Table 1.
Relevant laboratory findings of case 1 and case 2 before and after nilotinib therapy
| Case 1 |
Case 2 |
|||
|---|---|---|---|---|
| Laboratory parameters | Before nilotinib | 15th month of nilotinib therapy | Before nilotinib | 6th month of nilotinib therapy |
| Haemoglobin (11.7–17.0 g/dL) | 11.8 | − | 13.3 | − |
| Leucocyte (4.6–10.2×103/μL) | 62.30 | − | 26.30 | − |
| Neutrophil (2.0–7.0×103/μL) | 58.2 | − | 21.2 | − |
| Platelet (142.0–424.0×103/μL) | 349 | − | 233 | − |
| BCR/ABL (breakpoint cluster region-Abelson) | 90.1% | − | 92.0% | − |
| Jak2 mutation | Negative | − | Negative | − |
| Total cholesterol (130–200 mg/dL) | 150 | 300 | 150 | 147 |
| LDL cholesterol (60–130 mg/dL) | 90 | 220 | 82 | 80 |
| Triglycerides (50–150 mg/dL) | 100 | 180 | 94 | 90 |
Laboratory results falling out of the reference ranges are designated in bold
LDL, low-density lipoprotein.